Prostate cancer | Flatiron Health

Real-world overall survival and time to therapy discontinuation of patients with mCRPC treated with second-generation novel hormonal therapies associated with tissue-based comprehensive genomic profiling →

Graf, RP, Madison, RW, Gjoerup, O, Zhong, L, Morley, S, Chopra, S, Comment, L, Fisher, V, Li, G, MGregor, K, Schrock, AB, Tukachinsky, H, Snow, T, Cho-Phan, C, Swaminathan, A, Ross, JS, McCusker, M, Zurita, AJ, Venstrom, JM

February 2021

ASCO GU Symposium

Flatiron-authored

Real-world clinical outcomes study of sequential novel antihormonal therapy or radium-223 treatment of metastatic castration-resistant prostate cancer that progressed after first-line NAH →

Sartor, AO, George, DJ, Tombal, B, Higano, CS, Sternberg, CN, Miller, K, Jiao, X, Guo, H, Sandstrom, P, Verholen, F, Saad, F, Shore, ND

February 2021

ASCO GU Symposium

Overall survival of patients with metastatic castrate-resistant prostate cancer (mCRPC) who have PTEN tumor suppressor gene loss of function →

Gupta, S, Abbass, IM, Craggs, C, Satram, S, To, TM, Mahrus, S, Sufan, RI, Albarmawi, H

February 2021

ASCO GU Symposium

Real-world survival of men with metastatic hormone-sensitive prostate cancer treated with abiraterone acetate or docetaxel and comparison with clinical trial outcomes →

Geynisman, DM, Correa, AF, Ramamurthy, C, Beck, JR, Handorf, E

February 2021

ASCO GU Symposium

Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer →

Marar, M, Long, Q, Mamtani, R, Narayan, V, Vapiwala, N, Parikh, RB

February 2021

ASCO GU Symposium

The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies →

Shaw, JL, Nielson, CM, Park, JK, Marongiu, A, Soff, GA

February 2021

European Journal of Haematology

Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort →

Papillon-Cavanagh, S, Gao, C, Han, GC, Walsh, AM

May 2020

AACR Annual Meeting

Association of BRCA alteration type with real-world outcomes to PARP inhibitors in patients with metastatic castrate-resistant prostate cancer →

Antonarakis, ES, Madison, RW, Snider, J, Snow, T, Sokol, ES, Chung, JH, McCusker, M, Singal, G, Alexander, BM, Castellanos, EH, Venstrom, JM, Schrock, AB, Ross, JS

May 2020

ASCO Annual Meeting

Flatiron-authored

Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer →

Yang, DX, Leapman, MS, Gross, CP, Yu, JB

May 2020

ASCO Annual Meeting

Overall survival with docetaxel vs novel hormonal therapy with abiraterone or enzalutamide after a prior NHT in patients with metastatic prostate cancer: results from a real-world dataset →

Swami, U, Sinnott, J, Halland, B, Maughan, BL, Rathi, N, McFarland, TR, Kohli, M, Nussenzveig, S, Pal, SK, Agarwal, N

May 2020

ASCO Annual Meeting

Racial disparities in utilization and effectiveness of first-line therapies in metastatic castrate-resistant prostate cancer →

Marar, M, Mamtani, R, Narayan, V, Parikh, RB

May 2020

ASCO Annual Meeting

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer →

Shore, ND, Higano, CS, George, DJ, Sternberg, CN, Saad, F, Tombal, B, Miller, K, Kalinovsky, J, Jiao, X, Tangirala, K, Sartor, AO

May 2020

Prostate Cancer and Prostatic Diseases

Impact of previous local treatment for prostate cancer on subsequent metastatic disease: Comparative analysis and survival outcome

Shahait, M, Alshannaq, H, Dobbs, RW, Kim, J, Narayan, V, Lee, DI

April 2020

American Urological Association Annual Meeting

Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States →

George, DJ, Sartor, AO, Miller, K, Saad, F, Tombal, B, Kalinovsky, J, Jiao, X, Tangirala, K, Sternberg, CN, Higano, CS

January 2020

Clinical Genitourinary Cancer

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment →

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

ASCO Annual Meeting

Flatiron-authored

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone plus prednisone/prednisolone: A retrospective study of real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer →

Shore ND, Sartor AO, Sternberg CN, Saad F, Tombal BF, Miller K, Kalinovsky J, Jiao X, Tangirala K, Higano CS

June 2019

ASCO Annual Meeting

Treatment patterns and outcomes for metastatic castration-resistant prostate cancer in a real-world setting: A retrospective study of greater than 2500 patients →

Higano CS, Sternberg CN, Saad F, Tombal BF, Miller K, Kalinovsky J, Jiao X, TangiralanK, Sartor AO

February 2019

ASCO GU Symposium

Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients with metastatic castration-resistant prostate cancer →

George DJ, Sternberg CN, Sartor AO, Saad F, Tombal BF, Miller K, Kalinovsky J, Jiao X, Tangirala K, Higano CS

February 2019

ASCO GU Symposium

Clinical Outcome with Radium-223 (Ra-223) in Patients (pts) Previously Treated with Abiraterone (Abi) or Enzalutamide (Enza): A Retrospective Study of Real-World (RW) Data from pts with Metastatic Castration-Resistant Prostate Cancer (mCRPC) →

Higano C

October 2018

ESMO Annual Congress

An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer →

Liede A, Wade S, Lethen J, Hernandez RK, Warner D, Abernethy AP, Finelli A

February 2018

Clinical Therapeutics

Flatiron-authored

Treatment Dynamics of Bone-Targeting Agents Among Men with Bone Metastases from Prostate Cancer in the United States →

Butler A, Cetin K, Hernandez RK, Reams D, Overman R, Kim J, Hirsch B, Abernethy AP, Liede A, Brookhart A

January 2018

Pharmacoepidemiology & Drug Safety

Flatiron-authored

Concomitant use of emerging therapies and bone-targeting agents in prostate cancer: Observations from real-world data →

Finelli, A, Hernandez, RK, Lethen, J, Wade, SW, Warner, D, Abernethy, AP, Liede, A

June 2016

Meeting of the Canadian Urological Association

Flatiron-authored

Initiation and Adherence with Bone-Targeting Agents in US Men with Bone Metastases from Prostate Cancer →

Butler A, Ceitin K, Hernandez RK, Overman R, Kim J, Reams D, Hirsch B, Abernethy AP, Liede A, Brookhart A

June 2016

ASCO Annual Meeting

Flatiron-authored